The European Parliament voted 594-17 in favor of new regulations requiring drugmakers to make clinical data publicly available. Glenic Willmott, a sponsor of the measure, said the harmonization of rules in EU states is an important change, making it much easier to perform cross-border studies. The rules are "a triumph for transparency," said European Ombudsman Emily O'Reilly.

Related Summaries